0%
ClinicalInduced Pluripotent Stem Cells (iPSCs)Cancer Stem CellsStem Cell Differentiation

p53 Switches Off Pluripotency on Differentiation

Pmc

Key Findings

New findings reveal that the p53 protein is essential for guiding stem cells to differentiate safely, potentially reducing cancer risks.

By reactivating p53, researchers could enhance stem cell therapies and develop innovative cancer treatments, paving the way for safer regenerative medicine.

generated-image-1.jpg

# p53 Switches Off Pluripotency on Differentiation

## Abstract

The protein p53 is known as a protector of our cells, especially to prevent cancer. However, its role in early-stage stem cells, which can develop into different cell types, is less clear. This article explores the importance of p53 in these pluripotent stem cells, including how it affects their ability to differentiate and its implications for using stem cells in treatments. We discuss how p53 can both help in making stem cells safer and also play a role in cancer treatment, particularly in preventing cancer stem cells from forming.

## Highlights

- p53 plays a critical role in how stem cells differentiate and can potentially inhibit the development of cancer stem cells.

- Activation of p53 in stem cells is key for safety in stem cell therapies.

- Reactivating p53 could offer new strategies in cancer treatments.

## Background

For centuries, the idea of rejuvenation and the quest for eternal youth has been a captivating theme in stories. Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), offer incredible promise for regenerative medicine. iPSCs are developed from adult cells and can turn into any cell type, providing potential for replacing damaged tissues. However, there are concerns over their safety, especially regarding tumor risks.

## Role of p53 in Stem Cells

Research shows p53 is crucial in guiding how stem cells develop. Its activation can signal stem cells to stop dividing, thus promoting differentiation into other cell types. This is necessary to remove potentially damaged stem cells and, in turn, helps to prevent tumor development. However, overcoming the influence of p53 can allow stem cells to revert back to a pluripotent state, which raises questions about safety when used in therapies.

## Activation and Cancer Stem Cells

Reactivating p53 might not only help manage and prevent cancer but could also improve treatment strategies against cancer stem cells, which share traits with pluripotent stem cells. Therefore, understanding how to manipulate p53 might lead to safer and more effective therapeutic approaches.

## Conclusion

As p53 influences both the health of stem cells and their potential for tumor formation, understanding its role is essential in stem cell research and therapies. Future strategies could involve reactivating p53 to enhance the safety of stem cell applications and provide new ground for cancer treatment solutions. Monitoring the activities of p53 will be critical in ensuring the safe use of stem cells in regenerative medicine.

Research Details

Source

Pmc

Publication Date
Categories & Tags
ClinicalInduced Pluripotent Stem Cells (iPSCs)

Cite this article: Pmc. "p53 Switches Off Pluripotency on Differentiation". Published December 1, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5330084/

Access Original Research

View the complete study and detailed methodology from the original source.

Read Full Study

You Might Also Like

Explore more articles in this category

AI generated image for: Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial
2 min

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial

OBJECTIVE To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. METHODS We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. RESULTS AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. CONCLUSION Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints.

Neurology